Mutational analysis of E‐cadherin, β‐catenin and APC genes in synovial sarcomas

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Histopathology

• Publication date

  2010-09-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1111/j.1365-2559.2010.03626.xPMID 20840677
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Expression and prognostic significance of human growth and transformation-dependent protein in gastric carcinoma and gastric adenoma.

  2009cited by this paper
• Lysyl oxidase is essential for hypoxia-induced metastasis

  2006cited by this paper
• E-cadherin mutation and Snail overexpression as alternative mechanisms of E-cadherin inactivation in synovial sarcoma

  2004cited by this paper
• Identification of the Hypoxia-Inducible Factor 1α-Responsive HGTD-P Gene as a Mediator in the Mitochondrial Apoptotic Pathway

  2004cited by this paper
• Hypoxia-inducible factor 1alpha is essential for cell cycle arrest during hypoxia.

  2003cited by this paper
• Targeting HIF-1 for cancer therapy

  2003cited by this paper
• APC mutations in synovial sarcoma

  2002cited by this paper
• E-cadherin gene mutations frequently occur in synovial sarcoma as a determinant of histological features.

  2001cited by this paper
• Expression of cadherins and their undercoat proteins (alpha-, beta-, and gamma-catenins and p120) and accumulation of beta-catenin with no gene mutations in synovial sarcoma.

  2001cited by this paper
• Oxygen status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy.

  2001cited by this paper
• Expression of cadherins and their undercoat proteins (α-, β-, and γ-catenins and p120) and accumulation of β-catenin with no gene mutations in synovial sarcoma

  2001cited by this paper
• Prognostic value of the preserved expression of the E‐cadherin and catenin families of adhesion molecules and of β‐catenin mutations in synovial sarcoma

  2000influential reference
• Beta-catenin mutation in carcinoma of the uterine endometrium.

  1998cited by this paper
• Analyses of the APC and TGF‐β Type II Receptor Genes, and Microsatellite Instability in Mucosal Colorectal Carcinomas

  1997cited by this paper
• Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1

  1996cited by this paper
• E‐cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers.

  1995cited by this paper
• Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1.

  1994cited by this paper

• Innovative Breakthroughs for the Treatment of Advanced and Metastatic Synovial Sarcoma

  2023cites this paper
• Interdependence of SS18-SSX-driven YAP1 and β-catenin activation in synovial sarcoma.

  2023cites this paper
• WNT/β-Catenin Pathway in Soft Tissue Sarcomas: New Therapeutic Opportunities?

  2021influential citation
• Pathology of Sinonasal Tumors and Tumor-Like Lesions

  2020cites this paper
• Synovial Sarcoma: A Complex Disease with Multifaceted Signaling and Epigenetic Landscapes

  2020cites this paper
• The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma

  2019cites this paper
• Molecular Pathology of Sinonasal Tumors

  2019cites this paper
• Paracrine osteoprotegerin and &bgr;-catenin stabilization support synovial sarcomagenesis in periosteal cells

  2017cites this paper
• Synovial Sarcoma: Advances in Diagnosis and Treatment Identification of New Biologic Targets to Improve Multimodal Therapy

  2017cites this paper
• Next generation sequencing in synovial sarcoma reveals novel gene mutations

  2015cites this paper
• Synovial sarcoma: recent discoveries as a roadmap to new avenues for therapy.

  2015cites this paper
• Lysine-specific demethylase 1 (LSD1/KDM1A/AOF2/BHC110) is expressed and is an epigenetic drug target in chondrosarcoma, Ewing's sarcoma, osteosarcoma, and rhabdomyosarcoma.

  2012cites this paper
• Models of Biobanking and Tissue Preservation: RNA Quality in Archival Samples in Pathology Laboratories and “In Vivo Biobanking” by Tumor Xenografts in Nude Mice—Two Models of Quality Assurance in Pathology

  2011cites this paper